Investigations Operations Manual
FDA’s operational manual for its investigators, published so firms can see how the agency conducts inspections: the Notice of Inspection, records and photographs, the Form FDA 483 and its annotation, the close-out discussion and the Establishment Inspection Report.
What this does not cover
stated in the document's own scope- It describes what investigators do; it does not state what a firm must do. The firm’s obligations come from the FD&C Act and the regulations, such as 21 CFR Parts 210–211 or Part 820.
- It does not decide enforcement. Whether an observation is a violation, and what action follows, are agency decisions made after review; the IOM tells investigators not to characterise conditions as violative on the written observations.
- Records requests made in advance of or in lieu of an inspection under section 704(a)(4) follow separate procedures that Chapter 5 points to rather than sets out.
- Foreign inspections follow the same chapter with differences it names, for example that a Notice of Inspection is not required.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The Investigations Operations Manual is the primary operational reference for FDA investigators and other field staff. FDA publishes it so that regulated firms can understand how the agency works. For a firm it is the most direct account of what will happen during an FDA inspection: how the investigator opens it, what they may ask for, how they record and report what they see, and how the written Inspectional Observations are prepared, issued, annotated and discussed at close-out. The 2026 edition is current. Chapter 5, Inspections, is the chapter most firms use, and it carries general procedure plus program sections for foods, cosmetics, drugs, veterinary products, devices, biologics and bioresearch monitoring.
Scope & applicability
Field operations for every FDA-regulated product: inspections, sampling, imports, recalls and investigations. Chapter 5 covers inspections, with program sections for foods, cosmetics, drugs, veterinary products, devices, biologics and bioresearch monitoring. It instructs FDA staff; firms’ obligations come from the FD&C Act and the regulations.
Legal basis & how it acquires force
The IOM is an internal FDA staff manual, not a regulation and not guidance to industry. It binds investigators, not firms. The authority it operationalises is statutory: section 704 of the FD&C Act lets FDA enter and inspect at reasonable times, within reasonable limits and in a reasonable manner, requires the written report of observations before the investigator leaves (704(b)) and a receipt for samples (704(c)), and allows drug and device records to be requested in advance of or in lieu of an inspection (704(a)(4)). Section 501(j) makes a drug or device adulterated if its establishment delays, denies, limits or refuses an inspection.
Document structure
| Part | Covers |
|---|---|
| Chapters 1–3 | Administration; notes, records and information; and regulatory authority, including FDA’s statutory authority to inspect each product type |
| Chapter 4 | Sampling, including the Form FDA 484 receipt for samples |
| Chapter 5 — Inspections | Pre-inspection work, the Notice of Inspection (FDA 482), refusals and warrants, evidence (records, electronic data, photographs), written Inspectional Observations and their annotation, close-out discussion, the Establishment Inspection Report, and program sections by commodity |
| Chapters 6–8 | Imports, recall activities, and investigations |
| Chapters 9–10 and Appendix | Public health collaboration, investigator safety, and appendices |
Key requirements
- Credentials and a Form FDA 482 Notice of Inspection to the most responsible individual before a domestic inspection begins (IOM 5.5.1)
- A Form FDA 483 of significant objectionable conditions, issued at close-out before the investigator leaves, ranked by significance and without characterising conditions as violative (IOM 5.5.10–5.5.11)
- Annotation of the FDA 483 offered on every medical device inspection; voluntary for the firm (IOM 5.5.11.4, 5.12.1.5.6)
- Management advised that an adequate response within 15 business days of the inspection end date may affect FDA’s decision on subsequent action (IOM 5.5.12.3)
Implementation tips
- Read Chapter 5 with your own inspection-hosting procedure open beside it; every step the investigator takes should have a matching step in yours
- Train the people who will speak to an investigator on what the IOM says investigators may not do as well as what they may — they will not sign your documents, act as consultants, or show a draft 483
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The IOM works alongside the compliance programs, which define the scope of an inspection for a product area — for example CP 7356.002 for drug manufacturing, whose systems-based approach the IOM summarises — and alongside FDA’s Regulatory Procedures Manual, which governs what the agency does with the findings, including its advisory and enforcement actions. The 2026 edition reflects the device Quality Management System Regulation (21 CFR Part 820, effective 2 February 2026) and the Modernization of Cosmetics Regulation Act of 2022.
FDA IOM 2026: frequently asked questions
Quick answers to common questions about FDA IOM 2026.
Which edition of the IOM is current?
The 2026 edition, published on FDA’s Investigations Operations Manual page as a complete manual and by chapter. Its Foreword invites suggestions for the 2027 edition.
Does the IOM say how long a firm has to respond to inspectional observations?
It tells investigators to advise management that if FDA receives an adequate response within 15 business days of the end date of the inspection, it may affect FDA’s decision on the need for subsequent action (IOM 5.5.12.3). Responding is voluntary. FDA’s 2009 notice on post-inspection responses (74 FR 40211) sets the same 15-business-day window.
Can a firm refuse to let an FDA investigator take photographs?
The IOM tells investigators not to ask permission, because photography is part of the inspection authority under section 704(a)(1), and sets out how to handle an objection. For drug and device facilities, FDA’s guidance on delaying, denying, limiting or refusing an inspection treats impeding photography as a possible limitation unless there is a documented product-quality reason.
What is an annotation of the inspectional observations?
A short status note added to each observation at the close-out meeting, such as “corrected and verified” or “promised to correct by [date]”. The IOM requires the investigator to offer annotation on every medical device inspection; elsewhere it is at the program division’s discretion, and it is always voluntary for the firm.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.